EGFR and cancer: The present study investigated the efficacy of EGFR inhibiting compound 1e, using in‐vitro and in‐vivo methods, in potentiating doxorubicin‐mediated reduced tumorigenesis by sensitization of the breast CSCs toward chemotherapeutic to prevent the relapse of cancer.